Boris Sepesi
Overview
Explore the profile of Boris Sepesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
215
Citations
4714
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soto L, Lermi N, Ayala M, Ruiz S, Lu W, Khan K, et al.
Res Sq
. 2025 Jan;
PMID: 39877088
Imaging-based spatial transcriptomics (ST) is evolving rapidly as a pivotal technology in studying the biology of tumors and their associated microenvironments. However, the strengths of the commercially available ST platforms...
2.
Lermi N, Ayala M, Hernandez S, Lu W, Khan K, Serrano A, et al.
bioRxiv
. 2025 Jan;
PMID: 39763763
Imaging-based spatial transcriptomics (ST) is evolving rapidly as a pivotal technology in studying the biology of tumors and their associated microenvironments. However, the strengths of the commercially available ST platforms...
3.
Zhou N, Leung C, William Jr W, Weissferdt A, Pataer A, Godoy M, et al.
J Immunother Cancer
. 2024 Oct;
12(10.
PMID: 39448200
Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the...
4.
Rahal Z, Liu Y, Peng F, Yang S, Jamal M, Sharma M, et al.
Cancer Immunol Res
. 2024 Sep;
12(12):1736-1752.
PMID: 39269772
Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely coupled with tobacco-associated lung...
5.
Cascone T, Awad M, Spicer J, He J, Lu S, Sepesi B, et al.
N Engl J Med
. 2024 May;
390(19):1756-1769.
PMID: 38749033
Background: Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy)...
6.
Sewastjanow-Silva M, Xiao L, Gonzalez G, Wang X, Hofstetter W, Swisher S, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611056
Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve...
7.
Deboever N, Correa A, Feldman H, Eisenberg M, Antonoff M, Mehran R, et al.
Ann Surg
. 2024 Apr;
280(1):91-97.
PMID: 38568206
Objective: To investigate overall survival and length of stay (LOS) associated with differing management for high output (>1 L over 24 hours) leaks (HOCL) after cancer-related esophagectomy. Background: Although infrequent,...
8.
Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad M, et al.
JAMA Oncol
. 2024 Mar;
10(5):621-633.
PMID: 38512301
Importance: To date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non-small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there...
9.
Han G, Sinjab A, Rahal Z, Lynch A, Treekitkarnmongkol W, Liu Y, et al.
Nature
. 2024 Mar;
628(8006):E1.
PMID: 38499683
No abstract available.
10.
Salehjahromi M, Karpinets T, Sujit S, Qayati M, Chen P, Aminu M, et al.
Cell Rep Med
. 2024 Mar;
5(3):101463.
PMID: 38471502
[F]Fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are indispensable components in modern medicine. Although PET can provide additional diagnostic value, it is costly and not universally accessible, particularly...